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Abstract: The blood-related cancer leukemia was the first disease where human cancer stem cells (CSCs), or leukemic stem
cells (LSCs), were isolated. The hematopoietic system is one of the best tissues for investigating cancer stem cells, since the
developmental hierarchy of normal blood formation is well defined. Leukemia can now be viewed as aberrant hematopoietic
processes initiated by rare leukemic stem cells (LSC) that have maintained or reacquired the capacity for indefinite proliferation
through accumulated mutations and/or epigenetic changes. Yet, despite their critical importance, much remains to be learned
about the developmental origin of LSC and the mechanisms responsible for their emergence in the course of the disease. This
report will review our current knowledge on leukemic stem cell development and finally demonstrate how these discoveries
provide a paradigm for identification of Cancer Stem Cell (CSC) from solid tumors.
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Introduction
The hallmark properties of hematopoietic stem cells
(HSCs) are the ability to balance self-renewal versus
differentiation cell fate decisions to provide sufficient
primitive cells to sustain hematopoieisis, while genera-
ting more mature cells with specialized capacities.
Through the process of asymmetric cell division, a
single division can result in the formation of both an
identical stem cell and a more mature cell [10]. In order
to ensure a persistent pool of regenerating cells without
outgrowth of immature cell types, tight regulation of
HSC division is required. Unchecked growth of imma-
ture cells is thought to represent a paradigm for malig-
nant outgrowth, at least for acute myeloid leukemia
(AML) and chronic myeloid leukemia [16, 18]. Thus,
determining the composition and relationship of the cell
types that constitute the human stem cell compartment
may help both to identify the cellular and molecular
factors that govern normal and leukemic stem cell (LSC)
development, and to advance clinical applications of
transplantation, gene therapy, stem cell expansion and
tumor cell purging. This review will introduce the notion
of LSCs, the potential origin of these cells with an
emphasis on myeloid leukemia and finally examine the
impacts these discoveries may have clinically and in
understanding the organisation of cancer of other tis-
sues.
Functional heterogeneity in tumors 
The development of quantitative assays enabling meas-
urement of the clonogenicity of malignant hemato-
poietic cells led to the first demonstrations that only a
small subset of cancer cells is capable of extensive
proliferation in vitro [8]. Such studies revealed the ex-
istence of functional heterogeneity within tumors, and
introduced the concept of tumor stem cells. Sub-
sequently, studies in AML have been key in elucidating
the biological basis of tumor heterogeneity. AML is a
clonal disorder of aberrant hematopoiesis characterized
by an accumulation of functionally immature blasts,
which fail to differentiate normally. Despite their mor-
phological homogeneity, the blast cell population is
biologically heterogeneous. Only a minority of prolif-
erative leukemic blasts (AML-CFU) is able to give rise
to colonies in vitro. This observation suggested that, as
in normal hematopoiesis, the leukemic clone in AML is
organized as a hierarchy, in which a small number of
proliferating progenitors continuously replenish the
bulk population of non-cycling leukemic blasts. 
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Concept of leukemic stem cells 
Emerging evidence has provided new insights into
cancer biology by emphasizing the relationship between
stem cells and tumor cells and by proposing the notion
that cancer cells might contain some cancer stem cells,
which are rare cells with indefinite self-renewal poten-
tial that drive the formation and growth of the tumors.
The existence of cancer stem cells was revealed first in
leukemia [5, 14, 22] but has now extended to other
cancer types [1, 19, 20]. Transplantation of primary
AML cells into SCID [14] or NOD/SCID [5] mice led
to the finding that only rare cells, termed SCID leuke-
mia-initiating cells (SL-IC), are capable of initiating and
sustaining growth of the leukemic clone in vivo. In
addition to their ability to differentiate and proliferate,
serial transplantation experiments showed that SL-IC
possess high self-renewal capacity, and thus can be
considered to be AML stem cells. Importantly, SL-IC
can be prospectively identified and purified as
CD34+CD38- cells in AML patient samples, regardless
of the phenotype of the bulk blast population, and are the
only cells capable of self-renewal as demonstrate by
serial transplantation [5]. These findings show that, like
the normal hematopoietic system, AML is organized as
a hierarchy of distinct, functionally heterogeneous
classes of cells that is ultimately sustained by a small
number of leukemic stem cells (LSC). These studies
provided the first direct evidence for the cancer stem cell
hypothesis. 
Comparison between normal and leukemic
stem cells
While LSCs appear to share similar cell surface markers
previously identified for normal HSCs, such as CD34,
CD38, HLA-DR and CD71, several groups have re-
ported that some markers are differentially expressed
between the two such as CD90, Thy.1, c-kit and IL-3
receptor [2, 3, 4, 13]. Despite these few phenotypic
differences between normal HSC and LSC, a recent
work has reported similar heterogeneity in the normal
and LSC compartment based on self-renewal and pro-
liferation capacities. Using clonal tracking of retroviral-
transduced normal and leukemic cells in NOD/SCID
mice, it was demonstrated that both normal and LSC
compartments were comprised of individual stem cell
classes that differ in their repopulating and self-renewal
capacities [9, 11]. Overall, these findings suggest that
the pathways that regulate normal commitment/dif-
ferentiation and self-renewal processes in hematopoietic
cells are not completely abolished in LSC. Rather, the
effects of transforming mutations are layered onto the
normal developmental framework of HSC, resulting in
the leukemic clone having an aberrant developmental
hierarchy that retains aspects of its normal counterpart.
This concept is supported by a correlation between genes
required for normal hematopoietic development and
those perturbed in leukemia [23], and by the recent
demonstration that Bmi-1 plays a key role in self-rene-
wal determination in both normal and leukemic murine
stem cells [15, 17]. 
Gene expression pattern of LSC versus
normal HSC
The phenotypic description of LSC now enables their
purification and will facilitate identification of genes
that are preferentially expressed in these cells compared
to normal HSC. However, gene expression profiling is
usually conducted on mononuclear cells of AML pa-
tients from either peripheral blood and/or bone marrow.
Gene expression profile of highly purified LSC would
allow the identification of genes that reflect the biology
of the cells that are actually driving the leukemia. Hence,
in addition to being a more efficient way to further
understand the biology of LSC, this should also provide
a more efficient way of identifying new therapeutics and
diagnostic targets.
The cell of origin in cancer: studies in AML 
A focus of much cancer research is identification of the
normal cell within which cancer initiates. The target of
cell transforming mutations is still unknown. Because
normal stem cells and LSCs share the ability to self-
renew, as well as various developmental pathways, it has
been postulated that LSCs are HSCs that have become
leukemic as the result of accumulated mutations. Con-
versely, LSCs could derive from more committed pro-
genitors or even a differentiated mature cell, which
would have first to reacquire the self-renewal capacity
before accumulating additional mutations. 
There are two reasons to think that normal HSC
themselves are the target of leukemic transformation.
First, HSCs have the machinery for self-renewal already
activated thus maintaining this activation may be sim-
pler than turning it on de novo in a more differentiated
cell. Secondly, stem cells persist for long period of time
and thus have a greater opportunity to accumulate mu-
tations than more mature short-lived cell types. 
There is now evidence that most subtypes of human
AML arise from mutations that accumulate in HSCs. For
most AML subtypes, except for promyelocytic leukemia
(AML-M3) subtype, the only cells capable of transplant-
ing leukemia in nonobese diabetic/severe immunodefi-
cient mice (NOD/SCID) mice have a CD34+CD38-
phenotype, similar to that of normal HSC, whereas more
mature CD34+CD38+ leukemic blasts cannot transfer the
disease to mice [5, 22]. 
On the other hand, evidence indicating that cells
devoid of self-renewal activity, such as committed pro-
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genitors and mature cells, can also be the targets for
leukemic transformation comes from analyses of leuke-
mia-associated genes in the mouse. Indeed, using pro-
moter elements of several myeloid-specific human
genes (MRP8, CD11b, cathepsin G) to target transgene
expression specifically to committed myeloid cells,
allowed the generation of multiple accurate transgenic
mouse models of human leukemias [6, 12]. More recent-
ly, Cozzio et al. [7] have shown that the potent leukemic
fusion gene MLL-ENL, which results from the t (11; 19)
translocation, can induce the exact same leukemia when
transduced into HSCs as well as into CMPs and GMPs.
Another fusion gene MOZ-TIF2 has also recently been
shown to contribute to the transformation of both HSC
and more committed myeloid progenitors. These data
imply that myeloid leukemias induced by these on-
cogenes can be initiated in committed progenitors due
to their intrinsic capacities to confer leukemogenic self-
renewal potential. Using a different fusion partner of
MLL, GAS7, So et al. [21] showed that only the trans-
duction of murine HSC but not CMP, and GMP resulted
in the production of mixed lineage leukemias in trans-
planted mice. Although the mouse system provides a
valuable tool to study leukemogenesis, the data obtained
in mice do not imply that committed myeloid progeni-
tors will necessarily be the target of transformation in
the corresponding human disease. Nevertheless it ap-
pears highly probable that human AML might arise from
cells at both HSCs and myeloid stage depending mostly
on the nature of the associated fusion gene. 
Cancer stem cells in solid tumors 
Recent studies in solid tumors indicate that the con-
cept of cancer as a hierarchy that is initiated and
maintained by a rare population of stem cells may
have broader implications beyond the field of hema-
topoiesis. Al-Hajj et al. [1] were able to prospectively
isolate a minor phenotypically distinct subset of breast
cancer cells that was able to recapitulate the tumors
when transplanted into NOD/SCID mice. Thus like
AML, breast cancer appears to be driven by a rare
subpopulation of cells that demonstrate self-renewal and
produced differentiated non-tumorigenic progenies. A
recent report has also suggested the existence of brain
cancer stem cells, which are able to generate new tumors
in vivo that exhibit both self-renewal and differentiation
[19, 20]. 
Based on these recent studies, the paradigm of cancer
as a hierarchical disease whose growth is sustained by a
rare population of stem cells is emerging. Implicit in this
model of cancer development is the notion that CSC are
biologically distinct from other cells in the tumor, and
are able to initiate and sustain tumor growth in vivo
whereas the bulk cells are not. 
Conclusions
The identification of CSC has important implications for
future research as well as for the development of novel
therapies. In order to learn more about the nature of the
events involved in cancer, research should focus more
on CSCs and not on the bulk cells that makes up the
majority of the tumor. Existing therapies have been
developed largely against the bulk population. The lack
of durable response in most cases, suggests that the
treatment used may not effectively target the CSC popu-
lation. Indeed, the failure of the current therapeutic
regimens is likely related to the resistance and persist-
ence of CSC. Future studies must focus instead on
identifying and characterizing the rare cancer-initiating
cells, and cancer treatments must be designed to speci-
fically target these CSC if they are to effectively cure
and prevent disease relapse.
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